Products Markets Manufacturing Services Blog Who We Are Investor Relations English Home » Investor Relations » Corporate Governance » Articles of Association Articles of Association Your trusted and focused solution partner since 1923 Share Ticker Elos Medtech B (ELOS B) Latest +/- % Ask Bid 304 -16 -5.00 304 301 Last update: 4 December 2021, 9:23 This post is also available in: Svenska Articles of Association, adopted at the Annual General Meeting 3 May 2021 Article 1 The Company’s business name is Elos Medtech AB. The Company is a public limited liability company (publ). Article 2 The registered office of the Board of Directors shall be in the Municipality of Lidköping, Västra Götaland County, Sweden. Article 3 The Company shall – directly or through subsidiaries – conduct operations primarily in the business areas of medical technology, precision engineering, industrial electronics (assembly of electronic components and systems), injection moulding of thermo plastics, asset management and managing chattels and real property, and conduct other related operations. Article 4 The share capital shall amount to not less than SEK 20,000,000 and not more than SEK 80,000,000. The share shall be issued in two series, Series A, which can be issued at a number of not more than 9,200,000, and Series B, which Series B, which can be issued at a number of not more than 10,800,000. Each Series A share entitles the holder to one vote and each Series B share to one-tenth of a vote. All shares shall carry the same entitlement to a share in the Company’s assets and profit. It shall be possible to convert Series A shares to Series B shares, by the shareholder submitting a conversion request to the Company’s Board of Directors. The request shall state the number of shares that the holder wishes to convert and –unless the conversion pertains to the holder’s entire holdings of Series A shares – the shares that are to be converted. The Board of the Company shall be obliged to immediately address the issue of converting Series A shares into Series B shares, when this is request by a shareholder. Conversions shall be reported for registration without delay. If the Company decides to issue new Series A and Series B shares through a cash issue or an offset issue, holders of Series A and Series B shares shall have preferential rights to subscribe for new shares of the same type in relation to the number of shares already held (primary preferential right). Shares not subscribed for on the basis of primary preferential rights shall be offered for subscription to all shareholders (subsidiary preferential right). If the number of shares offered on this basis is insufficient for subscription based on subsidiary preferential rights, the shares shall be distributed in relation to the number of shares already held and, insofar as this is not possible, by lottery. If the Company decides to issue by cash or offset issue shares only of series A or series B, all shareholders, irrespective of whether their shares are of series A or series B, shall have preferential rights to subscribe for new shares in proportion to the number of shares owned prior to the issue. If the Company decides to issue warrants or convertible debentures through a cash issue or an offset issue, the shareholders shall have preferential rights to subscribe for warrants as if the new issue applied to the shares that may be issued on the basis of the warrants or with respect to convertibles as if the issue pertained to the shares for which the convertibles will be exchanged. The above stipulations shall not constitute any infringement on the possibility to make a decision regarding a cash issue or an offset issue whereby the shareholders’ preferential rights are disapplied. In the event of an increase in share capital through a bonus issue, new shares of each series shall be issued in relation to the number of shares of the same series already held. In such cases, existing shares of a specific series carry entitlement to new shares of the same series. The aforementioned stipulation shall not constitute any infringement on the possibility, following the requisite amendment in the Articles of Association, to issues shares of a new series through a bonus issue. Article 5 The number of shares in the Company shall not be fewer than 3,200,000 and not be more than 12,800,000. Article 6 The Company’s financial year shall be the calendar year. Article 7 At the General Meeting of shareholders, each voter is entitled to vote for the full number of shares owned and represented by the shareholder. Article 8 The Board of Directors comprises three to ten directors. Article 9 One to two auditors with or without deputies or a registered public accounting firm shall be appointed at the Annual General Meeting. The Board of Directors may appoint one or more specific auditors for examinations in accordance with Chapter 13, Section 8; Chapter 14, Section 10; Chapter 15, Section 10; Chapter 20, Section 14; Chapter 23, Section 11, and Chapter 24, Section 13 of the Swedish Companies Act (2005:551). Such a specific auditor is to be an authorised public accountant or a registered public accounting firm. Article 10 The Meeting shall be opened and directed by the Chairman of the Board, or the officer appointed specifically for this matter by the Board of Directors, until a Chairman of the Meeting has been elected. Article 11 General meetings of shareholders shall be held in Lidköping, Skara, Skövde, Gothenburg or Stockholm. The following items of business shall be addressed at the Annual General Meeting: election of Chairman of the Meeting. preparation and approval of the voting list. approval of the agenda. election of at least one minutes-checker. determination of whether the Meeting has been duly convened. presentation of the annual report and the auditors’ report and of the consolidated financial accounts and the auditor’s report on the consolidated financial accounts. resolutions concerning: adoption of the income statement and balance sheet and of the consolidated income statement and consolidated balance sheet. appropriation of the Company’s profit or loss in accordance with the adopted balance sheet. discharge of the Board directors and the President from personal liability. determination of the number of Board directors and auditors. determination of fees to be paid to the Board and the auditors. election of the directors of the Board and accounting firm or auditors. other matters to be considered at the Annual General Meeting in accordance with the Swedish Companies Act or the Articles of Association. Article 12 Notice of a General Meeting of shareholders shall be made in the form of an announcement in Post och Inrikes Tidningar and on the Company’s website. The announcement of the Notice of the AGM shall be advertised in Dagens Industri. Notice of the Annual General Meeting and Extraordinary General Meetings, at which matters regarding amendments to the Articles of Association are to be addressed, shall be issued not earlier than six weeks and not later than four weeks prior to the Meeting. Notice of all other types of Extraordinary General Meeting shall be made not earlier than six weeks and not later than three weeks prior to the Meeting. Article 13 The Company’s shares shall be registered in a securities register pursuant to the Swedish Financial Instruments Accounts Act (1998:1479). Shareholders or trustees who, on the record date, are entered in the shareholders’ register and noted in a control register shall be deemed to be authorised to exercise the rights detailed in Chapter 4, Section 39 of the Companies Act. Article 14 Shareholders who wish to participate in a General Meeting shall notify the Company not later than 12.00 p.m. on the date specified in the notice convening the meeting. This may not be a Sunday, public holiday, Saturday, Midsummer’s Eve, Christmas Eve or New Year’s Eve, nor may it fall less than five working days prior to the Meeting. Shareholders are entitled to be accompanied by one or two advisors, but only if the shareholder notifies the Company of the number of advisors in the manner stated above. Since the Company is a central securities depository (CSD) company, the right to participate at the General Meeting also falls to those registered as shareholders in the printout or other presentation of the share register pursuant to Chapter 7, Section 28, third paragraph of the Companies Act and that pertains to the status five working days prior to the Meeting. Article 15 The Board of Directors may collect powers of attorney in accordance with the procedure set out in Chapter 7. Section 4, second paragraph of the Swedish Companies Act (2005:551). Prior to a general meeting of shareholders, the Board of Directors may decide that shareholders shall be able to exercise their voting rights by post before the general meeting of shareholders. Article 16 The Board of Directors may decide that a person who is not a shareholder of the company shall, under the conditions laid down by the Board of Directors, have the right to attend or otherwise follow the proceedings at the annual general meeting. CALENDAR Feb 24, 2022 Year-end Report 2021 April, 2022 Annual Report 2021 April 26, 2022 Interim Report Q1, 2022 May 3, 2022 Annual General Meeting 2022 Aug 18, 2022 Interim Report Q2, 2022 Oct 21, 2022 Interim Report Q3, 2022 Feb 23, 2023 Year-end Report 2022 PRESS RELEASES & REGULATORY INFORMATION Notice to attend the Extraordinary General Meeting of Elos Medtech AB (publ) 29 Nov 2021, 16:30 Elos Medtech Interim Report January 1 - September 30, 2021 20 Oct 2021, 08:00 Elos Medtech Nomination Committee appointed for the 2022 Annual General Meeting 27 Sep 2021, 11:30 PRESS RELEASES & REGULATORY INFORMATION Notice to attend the Extraordinary General Meeting of Elos Medtech AB (publ) 29 Nov 2021, 16:30 Financial / IR information STAY UPDATED! Subscribe to our newsletter SUBSCRIBE Copyright © 2021 by Elos Medtech AB. All rights reserved. Cookies & Privacy Policy Follow us: This website uses cookies to provide you with the best browsing experience. Find out more or adjust your settings. Accept